Prospective, open label, randomized phase II trial to assess a multimodal molecular targeted therapy in children, adolescent and young adults with relapsed or refractory high-risk neuroblastoma
Study drugs: Rapamycin, Dasatinib, Temozolomide, Irinotecan
Version: 4.0
Status: Final
Date: 03.01.2014
